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Staphylococcus aureus is a gram-positive pathogen that is capable of expressing a variety of virulence proteins
in response to environmental signals. Virulence protein expression in S. aureus is controlled by a network of
regulatory loci including sarA and agr. The sarA/agr network is associated with the expression of cell wallassociated adhesins during exponential growth and the expression of secreted enzymes and toxins in the
transition to post-exponential growth. A number of sarA homologs, including sarT and sarS, have been
identified in the S. aureus genome. Previous studies have shown that sarA influences expression of both sarT
and sarS in the global regulatory network. SarS has been shown to bind to the spa promoter to induce
expression of protein A. SarT, one of the SarA homologs that represses hla expression and is repressible by
SarA and agr, was found to induce sarS expression in this report. Northern blot analysis of sarS and spa
expression in S. aureus RN6390, and the isogenic sarT, sarT sarA, and sarT agr mutants showed that while sarA
regulated spa expression directly, the agr locus used sarT as an intermediary to regulate sarS, thus leading to
spa repression in agr-activated cells. Gel shift and footprinting analysis showed that SarT binds to the sarS
promoter, indicating that the interaction of the sarT gene product with the upstream region of sarS is likely
direct. Induction of sarS and spa by SarT in agrⴙ strains was confirmed by a tetracycline-inducible system to
titrate sarT expression.
and virulence genes is associated with the transition from exponential to post-exponential phase of growth (21).
The agr locus (Fig. 1) is a pleiotropic regulator for the
synthesis of exoproteins as well as a repressor of cell wall
synthesis during the post-exponential phase (10, 23, 25, 27, 42,
46). The agr locus encodes two divergent transcripts, RNAII
and RNAIII, originating from two adjacent promoters, P2 and
P3, respectively (27, 41) (Fig. 1). RNAII encodes four genes,
agrB, -D, -C, and -A, which comprise the genetic elements of a
two-component quorum-sensing system (25, 30, 38). The
RNAII gene product AgrD encodes a 46-residue peptide that
is processed to a cyclic peptide (autoinducing peptide [AIP])
by AgrB and exported (24, 25). AgrC is a transmembrane
sensor that is autophosphorylated when activated by a threshold concentration of AIP and, in turn, activates AgrA, the
response regulator for transcriptional activation of the agr P2
and P3 promoters (30, 41). The P3 promoter mediates transcription of RNAIII, the agr regulatory molecule. RNAIII
mRNA forms a complex three-dimensional structure containing multiple loops that are believed to control transcription
and under certain circumstances, translation of exoprotein
genes by binding to specific target sites (5, 23, 37, 42).
The agr P2-P3 interpromoter region, in addition to selfactivation via AgrA, is also activated by SarA, the sarA gene
product (16). The sarA locus consists of a 372-bp open reading
frame driven by three sequential promoters (P2, P3, and P1)
(4, 34) (Fig. 1a). Due to their overlapping nature, all three
transcripts encode the sarA open reading frame. The P2 transcript encodes the entire sarA locus, including the triple promoter region (11). The P1 and P2 promoters are active during
exponential and late exponential growth, while the P3 promoter is most active during the post-exponential phase and is
regulated by B, a stress-induced transcription factor (34).
Protein-DNA binding studies revealed that SarA binds to a

Throughout in vitro growth, and presumably during an infection, Staphylococcus aureus responds to environmental signals by selectively generating specific virulence proteins. During the exponential phase in vitro, S. aureus synthesizes surface
proteins that mediate attachment, including protein A, fibrinogen, and fibronectin binding proteins (27, 45). In an infection,
bacterial attachment would facilitate active colonization and
formation of bacterial vegetations within the host (15, 27, 45).
As the cells enter the post-exponential phase in vitro, proteins
mediating attachment are repressed, while S. aureus synthesizes exoproteins (including hemolysins, toxins, proteases, and
lipases) capable of causing host cell tissue damage (21, 47). By
lysing host cells, proteins expressed in the post-exponential
phase likely aid in the acquisition of additional nutrients and
facilitate dissemination of S. aureus in vivo (45). A complex
regulatory network, with many linked components apparently
imparts precise and flexible coordination of protein expression
in response to the microenvironment (1, 9, 36). The activation,
repression, and interactions of the regulatory genes must be
understood to develop a comprehensive picture of the infectious process and disease development.
The sarA and agr loci comprise a primary global regulatory
system that coordinates synthesis of cell wall and extracellular
virulence proteins during late exponential and post-exponential phases (1) (Fig. 1). Transcriptional profiling studies comparing sarA and agr mutants with wild-type cells at different
growth phases indicate that in addition to the virulence proteins, sarA and agr regulate expression of a number of genes
involved in metabolic processes, and activation of metabolic
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gest that SarT is a positive regulator of sarS and the ensuing
spa expression.
MATERIALS AND METHODS

FIG. 1. A simple overview of the predicted sarA/agr regulatory web
involving SarT and SarS. (a) SarA is transcribed from one of three
nested promoters (P1, P2, or P3). (b) SarA represses expression of spa
(protein A) and sarT (17, 48, 49) and induces agr RNAII (19, 38). (c)
agr RNAII encodes a two-component quorum-sensing system, which
activates expression of agr RNAIII, a pleiotropic regulator for expression of proteins associated with virulence (23, 27, 42, 46). (d) agr
RNAIII represses sarT. (e) Increased expression of sarT causes repression of sarU, particularly during exponential growth (35). (f) sarU
induces expression of agr RNAIII (35). (g) SarT represses expression
of hla (48). (h) SarT induces expression of sarS (this study), and sarS
induces expression of spa (17). The conditions and regulators mediating induction of sarT have not yet been determined.

29-bp sequence in the agr P2-P3 interpromoter region (Fig.
1c), activating agr RNAII and RNAIII transcription (19, 38).
While the sarA/agr system is the major controlling element
for the expression of a variety of virulence proteins during the
growth cycle (10, 13, 20), a series of other SarA-like proteins,
discovered by promoter trap and genomic scanning, also appear to interact within the sarA/agr global regulatory network.
Examples of these SarA homologs include sarR, which appears
to repress sarA expression by binding to the sarA P1 and P3
promoters (33), and sarS, which induces spa (protein A) transcription (17, 49) (Fig. 1i). sarT, which is repressed by sarA and
agr (Fig. 1b and d), has been shown by Northern blot, Western
blot, and hemolytic assays to repress hla, the gene encoding
␣-hemolysin (48) (Fig. 1g). Interestingly, even though sarT is
repressed by agr, it was shown both by Northern blotting and by
a promoter-reporter system that repression of sarT could result
in up-regulation of sarU, an activator of RNAIII, thus implying
a positive-feedback control loop (35, 48) (Fig. 1e and f).
The sarS locus, adjacent to the spa gene, has been linked
with spa induction (17, 49) (Fig. 1i). In this study, we showed
that expression of SarT was accompanied by increased transcript levels of sarS and spa. Northern blot analysis of sarS and
spa expression in S. aureus RN6390 and the isogenic sarT, sarT
sarA, and sarT agr mutants showed that while sarA regulates
sarS and spa expression directly, agr utilizes sarT to downregulate sarS and thereby repress spa expression (Fig. 1h). Gel
shift and DNA footprinting analysis revealed that purified
SarT protein binds specifically to the sarS promoter region.
Importantly, sarS and spa expression was induced in a dosedependent manner when sarT expression was driven by a tetracycline-inducible promoter. Taken together, these data sug-

Bacterial strains, plasmids, and growth media. The bacterial strains and
plasmids used in this study are listed in Table 1. Phage 80␣ (39) was used as a
transducing phage. Escherichia coli strains were grown in Luria-Bertani (LB)
medium (32). S. aureus strains were maintained in tryptic soy medium (Difco)
and grown in CYGP or 03GL medium (39). Erythromycin (5 g/ml), chloramphenicol (34 g/ml in E. coli and 10 g/ml in S. aureus), tetracycline (5 g/ml),
ampicillin (50 g/ml), and kanamycin (50 g/ml) were used for selection of
transformants and transductants.
Generating a sarT mutant. The tetK gene was cloned from pT181 (26) using
the primers 5⬘-GAT AAA AGA AAT TTC GCC AGT C-3⬘ and 5⬘ ACG CGT
CGA CAC TCG TTA ATA CGT GTG CTC TG-3⬘ and ligated into pCR2.1
(Invitrogen, San Diego, Calif.). tetK was ligated into a blunted NdeI site within
the sarT coding region of pALC1894 (48), the insertion was confirmed by DNA
sequencing, and the resulting 4.9-kb fragment containing tetK inserted into the
sarT region was ligated into pBT2 (7). The resulting plasmid, pALC2229, was
electroporated into S. aureus RN4220 and propagated through several cycles of
alternating the temperature between 30 and 42°C as described elsewhere (8).
Chloramphenicol-sensitive, tetracycline-resistant colonies, representing possible
double-crossover events, were selected (14) and screened for tetK insertion into
sarT by Southern blotting and by sequencing of the PCR fragment containing the
junctional fragment. The S. aureus RN4220 sarT::tetK mutant (ALC2313) was
used as the source for transduction of the sarT::tetK mutation to other S. aureus
strains.
The sarT mutant of S. aureus SH1000 was generated by transducing strain
SH1000 with an 80␣ phage lysate of S. aureus ALC2313 as previously described
(14, 50). To confirm the genotype, chromosomal DNA from S. aureus cultures
grown overnight was isolated by lysostaphin lysis and phenol extraction as described previously (14). DNA extracts of the putative transductants were digested
with restriction enzymes and screened by Southern blotting for the presence of
antibiotic resistance genes and shifts in the sizes of restriction digest fragments
as previously described (48). Northern blot analysis with relevant DNA probes
confirmed the loss of RNA message.
RNA analysis. Cells were grown to exponential (optical density at 650 nm
[OD650] of 0.7), late exponential (OD650 of 1.1), and postexponential (OD650 of
1.7) phases, and RNA was extracted using the Trizol isolation procedure (Gibco
BRL, Gaithersburg, Md.) as previously described (18, 28, 48). RNA concentrations in the extracts were determined by absorbance at 260 nm using an Eppendorf BioPhotometer (Brinkmann, Westbury, N.Y.). Part (20 or 30 g) of each
sample was electrophoresed through a 1.5% agarose–0.66 M formaldehyde gel in
4-morpholinepropanesulfonic acid (MOPS) (Roche Diagnostics, Indianapolis,
Ind.) buffer (20 mM MOPS, 10 mM sodium acetate, 2 mM EDTA [pH 7.0]) and
blotted onto Hybond-N⫹ membranes (Amersham, Arlington Heights, Ill.) as
previously described (16). Prior to blotting, the gel was viewed under UV light to
ensure that equivalent amounts of ethidium bromide-stained rRNA bands were
present for each sample. After blotting, the gel was viewed under UV light to
confirm complete RNA transfer. Northern blots were probed with radiolabeled
DNA probes for the detection of sarT, sarS, RNAIII, hla, spa and HU (a
housekeeping transcript) transcripts as previously described (48). The HU transcript served as an internal gel loading control (20, 27).
Cell wall-associated proteins. Staphylococcal strains were grown overnight in
CYGP broth and washed, and the cell density was adjusted to an OD650 of 1.0 in
PBS. Cell wall-associated proteins were extracted after lysostaphin digestion in a
hypertonic buffer (0.05 M Tris, 0.145 M NaCl, 30% raffinose [pH 8.0]) with
protease inhibitors as previously described (13). Equivalent amounts of cell wall
extracts were separated by electrophoresis on sodium dodecyl sulfate–10% polyacrylamide gels and transferred to nitrocellulose membranes by electroblotting.
To detect protein A, nitrocellulose blots that had been incubated overnight in
bovine serum albumin (BSA) blocking buffer (19) were incubated with affinitypurified chicken anti-protein A antibody (1:3,000 dilution) (Accurate Chemicals,
Westbury, N.J.) and then with an alkaline phosphatase-conjugated F(ab⬘)2 fragment of sheep anti-chicken immunoglobulin G (Jackson Immunoresearch, West
Grove, Pa.). Reactive bands were detected by incubating the blot with Nitro Blue
Tetrazolium (NBT)/5-bromo-4-chloro-3-indolylphosphate (BCIP) substrate
(Sigma Chemical Co., St. Louis, Mo.). Band intensities were determined by
densitometric scanning using SigmaGel software (Jandel Scientific, San Rafael,
Calif.), with the data presented as integrated area units (IAU).
Expression and purification of SarT. The 420-bp DNA fragment containing
the sarT coding region was cloned from S. aureus RN6390 chromosomal DNA by
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TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid

S. aureus
8325-4
RN4220
RN6390
RN6911
SH1000
ALC1905
ALC1927
ALC2009
ALC2056
ALC2057
ALC2071
ALC2076
ALC2122
ALC2150
ALC2221
ALC2235
ALC2236
ALC2253
ALC2254
ALC2255
ALC2305
ALC2313
ALC2389
ALC2394
ALC2398
ALC2399
ALC2402
Plasmids
pALC1894
pALC2047
pALC2073
pALC2217
pALC2223
pALC2229
pACL2321

Description

Reference(s)

Prophage-cured strain of NCT8325, harboring an 11-bp deletion in rsbU, which regulates
sigB activity by activating rsbV, a factor that competitively binds to the anti-sigma
factor RsbW
Mutant strain of 8325-4 that accepts foreign DNA
agr⫹ laboratory strain related to 8325-4
agr mutant of RN6390 (⌬agr::tetM)
8325-4 with intact rsbU
sarT mutant of RN6390 (sarT::ermC)
sarS mutant of RN6390 (sarS::ermC)
ALC1927 with pSK236 containing a 1.2-kb sarS coding region fragment
agr sarT mutant of RN6390
RN6390 sarA::kan
ALC1905 with pALC2047
ALC2056 with pALC2047
ALC2057 with sarT::ermC (sarA sarT)
ALC2122 with pALC2047
ALC1905 with pALC2217
ALC2056 with pALC2217
ALC2122 with pALC2217
ALC2122 with pALC2073
ALC2056 with pALC2073
ALC1905 with pALC2073
RN4220 with pALC2229
RN4220 sarT::tetK
sarT mutant of SH1000 (sarT::tetK)
ALC2389 with pALC2047
RN6390 with pALC2047
ALC2389 with pALC2217
ALC2389 with pACL2073

39
39
42
22
48
15
17
48
48
48
48
48
48
This
This
This
This
This
This
This
This
This
This
This
This
This

study
study
study
study
study
study
study
study
study
study
study
study
study

pUC18 with 3.2-kb fragment containing the sarT coding region
pSK236::sarT
pSK236::xyl/tetO promoter::tetR
sarT ligated into the EcoRI and SstI sites of pALC2073
pALC1894 containing the sarT mutation (sarT::tetK)
pBT2 with the sarT mutation (sarT::tetK)
pCR2.1 Topo with the sarS promoter fragment

48
48
3
This
This
This
This

study
study
study
study

PCR with the primers 5⬘-GTA AGG GAT GAA CTC GAG ATG AAT GAT
TTG AA-3⬘ and 5⬘-ACG GGG ATC CAA AAA TAC ATT TAA CTG CAC
CAA-3⬘, ligated into the XhoI and BamHI sites of pET14b (Novagen, Madison,
Wis.), and transformed into BL21 (Novagen). Proper insertion of the sarT gene
into the recombinant plasmid was confirmed by restriction digestion and by
sequencing (Novagen). Protein expression was induced in broth culture with 1
mM isopropyl-␤-D-thiogalactopyranoside (IPTG), the cells were harvested and
lysed, and the protein was purified on a His-Tag column following the manufacturer’s protocols (Novagen). The purity of SarT was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the authenticity was verified by microsequencing the first 10 amino acids of the purified, thrombincleaved protein (48).
Doxycycline induction. The effects of SarT on target gene expression were
evaluated with a tetracycline-inducible promoter system to yield a gradient of
sarT expression. The sarT coding region, together with the upstream ribosomal
binding site, was ligated downstream of the xyl/tetO promoter in pALC2073, a
derivative of pSK236, containing the tetR repressor (3). Insertion was confirmed
by restriction mapping and DNA sequencing. sarT mutant strains were transformed with the resulting tetracycline-inducible sarT-expressing plasmid
(pALC2217) or with pALC2073 as a control. Cultures of the sarT mutant strains
harboring the plasmids (cultures had been grown overnight in broth) were
diluted 1:100 in CYGP medium and incubated with shaking at 37°C. To capture
differential expression during the transition from the late exponential phase
(OD650 of ⬵1.4) to the post-exponential phase (OD650 of ⬎1.7), the cultures
were grown to an OD650 of 1.1 and doxycycline was added at concentrations of
0, 35, and 50 ng/ml to induce gene expression. Cultures were harvested for RNA
analysis 1 and 2 h after the addition of doxycycline (48). Northern blots of RNA

39, 42

from the above strains were probed with 32P-labeled specific gene fragments as
previously described (16) for the detection of sarT, sarS, and spa transcripts.
DNA gel shift assay of SarT with the sarS promoter. The binding of SarT to the
sarS promoter was confirmed by gel shift assays. A DNA fragment encompassing
the sarS promoter region (49) was cloned using the primers 5⬘ CCC GGT ACC
TAT TAC GCT TAC CTC GCT TTA-3⬘ and 5⬘-CCC GGA TCC TTT CAT
TGT TTT ATC TC-3⬘, ligated into pCR2.1 Topo (Invitrogen, Carlsbad, Calif.),
and confirmed by sequencing. A plasmid harboring the sarS promoter region
fragment (pALC2321) was digested with SalI and EcoRI to yield a 264-bp
fragment (nucleotides [nt] 125169 to 125432) (29) for use in gel shift experiments. The gel-purified fragment was dephosphorylated and then end labeled
with [␥-32P]ATP using T4 polynucleotide kinase (U.S. Biochemical Corp, Cleveland, Ohio). The labeled fragment was incubated with various concentrations of
purified SarT protein and analyzed by nondenaturing polyacrylamide gel electrophoresis as previously described (33). Controls were BSA, the sarA P3 promoter fragment as the nonspecific competitor, and unlabeled sarS promoter
fragment as the specific competitor.
DNase I footprinting. DNase I footprinting assays with a 287-bp DNA fragment encompassing the promoter region upstream of sarS were performed as
previously described (20). The top-strand primer 5⬘-ACA TCT AGA TGT TGT
TAT TGT TAA CAA GCG ⫺3⬘ at positions ⫺288 to ⫺259 from the translational start site (ATG) and the bottom-strand primer 5⬘-CTG TCC ATG GTT
TTA TCT CCT TGT ATA TGC AC-3⬘ at positions ⫺2 to ⫺33 from the
translational start site were used to amplify the sarS promoter region. To label
the PCR product, only one of the primers was end labeled prior to the PCR. For
the assay, the binding reactions were performed in the 100-l reaction volume
containing 20 mM Tris-Cl (pH 8.0), 100 mM NaCl, 5 mM MgCl2, 1 mM CaCl2,
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FIG. 2. Effects of sarT mutation on expression of sarS and spa. Northern blots of RNA extracted from S. aureus RN6390 (6390) (A) and SH1000
(B) and their isogenic sarT mutant and sarT-complemented strains were hybridized with sarT, sarS, spa, or HU probes. RNA was extracted during
late exponential (OD650 of 1.1) and postexponential (OD650 of 1.7) phases of growth. Results are representative of multiple Northern blots,
utilizing RNA extracts from multiple experimental sets as previously described (48). HU is constitutively expressed and served as an internal
loading control (20, 27). Band density measurement for HU had a mean IAU of 3,455 (standard deviation, 498). The presence of pALC2047, a
plasmid bearing an intact sarT, is indicated by cp T (for complementation in trans).

2 mM dithiothreitol, 10 g of BSA, 0.4 g of calf thymus DNA, radiolabeled
template DNA (10,000 cpm for each reaction), and various amounts of purified
SarT at room temperature for 30 min. DNase I (0.02 U) (Boehringer GmbH,
Mannheim, Germany) was added and allowed to incubate for 1 min at room
temperature. The reaction mixtures were extracted with phenol-chloroform,
ethanol precipitated, washed with 70% ethanol, dried, and resuspended in loading buffer (98% deionized formamide, 10 mM EDTA [pH 8.0], 0.025% [wt/vol]
xylene cyanol FF, 0.025% [wt/vol] bromophenol blue). The samples were denatured at 95°C for 5 min and analyzed on a 6% denaturing polyacrylamide
sequence gel. Positions of the protected region were derived by comparing the
footprint with the A⫹G sequencing ladder of the same fragment (34).
Densitometry. Blots were scanned with an Hewlett-Packard desktop scanner
set at 200 dots per inch. Band density was determined from the scan image using
the SigmaGel (Jandel Scientific) software. Graphs were drawn using Excel (Microsoft). Blot scans were processed into figures using Adobe Photoshop LE
(Adobe Systems Inc., San Jose, Calif.).

RESULTS
Effects of sarT on sarS and spa expression. In a previous
study (48), we generated a sarT mutant harboring a plasmid
(pALC2047) bearing the sarT gene (sarT in trans) that expressed a high level of SarT. We noted that on a Northern blot,
the complemented sarT mutant strain (S. aureus ALC2071
[sarT cpT]) expressed high levels of sarS and spa messages
during late exponential and post-exponential growth phases,
concomitant with increased sarT expression in these strains
(Fig. 2A). The same pattern was obtained when parental strain
RN6390 was transformed with pALC2047 (6390 cp T [Fig.
2A]). As has been found previously (12), strain RN6390 was a
low protein A producer, as evidenced by our failure to detect
a significant level of spa transcription in this strain at both
growth phases (OD650s of 1.1 and 1.7 [Fig. 2A]).

S. aureus RN6390 harbors an 11-bp deletion in rsbU, a gene
encoding an anti-sigma factor that, when activated, increases
sigB expression approximately 50% (43). B has been implicated in regulating expression of sarA and agr (Fig. 1a) (6, 22).
Since sarA and agr expression influence expression of sarT and
sarS (17, 48) (Fig. 1b and d), we wanted to confirm that the
effect of sarT on sarS in strain RN6390 was not due to the
mutation in rsbU. Accordingly, a sarT mutant was generated by
transducing the sarT mutation into S. aureus SH1000 (S. aureus
8325-4 rsbU⫹ [22], kindly provided by S. J. Foster), using phage
80␣.
In Northern blots of late exponential and post-exponential
RNA of S. aureus SH1000, expression of sarT and sarS was not
detected (Fig. 2B). Interestingly, spa expression was detected
during the post-exponential phase (OD650 of 1.7), but not at
the late exponential phase (OD650 of 1.1) (Fig. 2B). In the
SH1000 sarT mutant, neither sarS nor spa expression was detected (Fig. 2B). Complementation of the sarT mutant of
SH1000 in trans resulted in increased expression of sarS and
spa, particularly during the late exponential phase at an OD650
of 1.1 (Fig. 2B). Since sarS was expressed at equivalent levels
in both the RN6390 and SH1000 sarT-complemented mutant
strains (the sarS band density for RN6390 sarT-complemented
mutant was 869 IAU versus 898 IAU for the SH1000 sarTcomplemented mutant at the post-exponential phase) (Fig. 2),
B activity does not appear to directly affect the relationship
between sarT and sarS. However, in the complemented sarT
mutant, the expression of spa was lower than in the RN6390
counterpart. Although SarA has been shown to be a direct
effector of spa expression (Fig. 1b) (12), the discrepancy in spa
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FIG. 4. Expression of sarS and spa in agr, sarA, agr sarT, and sarA
sarT mutant strains. RNA extracts from S. aureus taken at exponential
(OD650 of 0.7), late exponential (OD650 of 1.1), and postexponential
(OD650 of 1.7) phases of growth were hybridized with sarS and spa
probes. sarT and sarA mutant strains (A) and sarT and agr mutant
strains (B) are shown. Results are representative of multiple Northern
blots utilizing RNA extracts from multiple experimental sets as previously described. 6390, RN6390; cp T, complemented with sarT in trans.

FIG. 3. Effects of sarS mutation on sarT, RNAIII, and hla expression. (A) Northern blots of RNA extracted from S. aureus RN6390 and
isogenic mutants at late exponential (OD650 of 1.1) and postexponential (OD650 of 1.7) phases of growth and probed with sarT, RNAIII, or
hla probe. Results are representative of Northern blots made from
three independently isolated sets of RNA extracts. cpT, complemented
with sarT in trans; cpS, complemented with sarS in trans. (B) RNAIII
and spa signals quantified by densitometry. The mean IAU for the HU
bands was 3,849 (standard deviation, 306).

expression between RN6390 and SH1000 cannot be attributed
to the effect of B on sarA expression alone.
Effect of sarS on sarT. While sarT appears to influence sarS
expression, we wondered if sarS, in turn, modulates sarT. We
thus examined the expression levels of sarT and of agr RNAIII
and hla, two targets of sarT repression (48), in a sarS mutant
and its sarS-complemented counterpart (S. aureus ALC2009)
(17). As with S. aureus RN6390, sarT expression was not detected in either the sarS mutant or its isogenic sarS-complemented strain (Fig. 3A). Further, the expression levels of hla
and RNAIII, target genes of sarT, did not vary substantially
from the RN6390 levels in either the sarS mutant or its isogenic

complement (Fig. 3). In contrast to RN6390, the parental
strain (which has a single copy of sarT), the sarT mutant expressing sarT from a multicopy plasmid in trans expressed
considerably lower levels of hla and RNAIII during the late
exponential and post-exponential phases (Fig. 3). These results
are consistent with the previous observation that sarT is a
repressor of hla (48) and RNAIII by virtue of a feedback loop
involving sarU (35) (Fig. 1).
In a previous study (48), expression of hla and RNAIII in a
sarT mutant of S. aureus RN6390 was approximately double
the levels seen for RN6390. As agr RNAIII and hla expression
levels in the sarS mutant and its isogenic complemented strain
did not differ substantially from those seen in RN6390 (Fig.
3B) and since any significant alterations in sarT expression
would be reflected in changes in RNAIII (sarT 1 3
RNAIII2) and hla (sarT2 3 hla1) expression, these data
are consistent with the hypothesis that sarS does not exert any
great inductive or repressive effect on sarT.
Effects of sarA and agr mutations. In the regulatory pathway
(Fig. 1), SarA has been found to repress sarT (48), thus accounting for increased transcript levels of sarT in the sarA
mutant compared to the parent (Fig. 4A). To determine
whether SarA represses spa directly (SarA13 spa2) or indirectly via sarT (SarA13 sarT2 3 sarS2 3 spa2), a double
sarT sarA mutant was generated and tested for sarS and spa
expression in S. aureus RN6390. Expression levels of sarS and
spa remained high in the sarA sarT double mutant compared
with the single sarA mutant (Fig. 4A). As expected, sarS and
spa expression was not readily detected in the sarT mutant.
This suggests that sarA is repressing spa directly, rather than
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FIG. 5. Western blot of S. aureus cell wall-associated protein extracts probed with chicken anti-protein A antibody. Equivalent
amounts of cell wall extracts were applied to the lanes, electroblotted,
and probed with chicken anti-protein A antibody as described in the
text (17, 48). The positions of standard protein molecular mass standards (Std) (in kilodaltons) are shown to the left of the blot. The
positions of intact protein A (large arrowhead) and degraded protein
A bands (small arrowheads) are shown to the right of the blot. Results
are representative of two independent experiments. 6390, RN6390;
cpT, complemented with sarT in trans.

indirectly via sarT and sarS (Fig. 1), since a sarA sarS double
mutant has previously been found to express a high level of spa
despite the absence of sarS (17, 49).
Previous studies also showed that transcription levels of sarS
(17) and spa are increased in an agr mutant (12, 23). The
transcription of spa is also reduced in the agr sarS double
mutant, demonstrating that agr represses spa expression probably by repressing sarS, an activator of spa (17). To ascertain
whether sarT induces sarS directly in an agr mutant (agr2 3
sarT1 3 sarS1) (Fig. 1), we generated an agr sarT double
mutant and compared sarS and spa expression with expression
in the isogenic single agr mutant (Fig. 4B). In the agr sarT
double mutant, sarS and spa expression levels were reduced
from those of the agr mutant during both exponential and
post-exponential growth. Importantly, the absence of sarS in
the double mutant correlated with notably reduced spa expression. Complementing the double agr sarT mutant with sarT in
trans resulted in increased levels of sarS and spa expression
compared to those of the double agr sarT mutant (Fig. 4B),
particularly in the post-exponential growth phase. The same
expression pattern was also seen in agr sarT and sarT-complemented double mutants of SH1000 (data not shown). Collectively, these data suggest that the increase in spa expression
seen in an agr mutant is likely the result of sarT induction of
sarS. As expression of sarT also has a mild repressive effect on
agr (48), the decreased sarS message in an agr sarT double
mutant also indicated that the high levels of sarS message in an
agr mutant was not due to repression of agr RNAIII by SarT
(i.e., SarT1 3 agr2 3 sarS1).
Cell wall-associated protein A. We also confirmed the
Northern blot results by analyzing protein A levels in postexponential-phase cultures of S. aureus RN6390 (cultures
grown overnight) with immunoblots (Fig. 5). Consistent with
the spa message detected in the Northern blots, levels of cell
wall-associated protein A were not detected in the parental
RN6390 and sarT and sarS mutant strains. The intensity of the
protein A band in the sarT mutant strain harboring sarT in
trans (870 IAU) was consistent with the light spa band seen on
the Northern blot (Fig. 4B). The intensity of the protein A
band in the agr sarT mutant was lower (1,038 IAU) than that
seen in the agr mutant strain (1,350 IAU). However, the protein A band of the agr sarT mutant on the immunoblot seemed
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higher than what one would expect from the level of spa transcription on the Northern blot (Fig. 4B). This could conceivably be explained by technical differences, since cell wall protein A tends to accumulate throughout the growth cycle, while
the Northern blot data are expected to reflect spa expression at
a single time point during growth (Fig. 4).
As has been noted previously (17, 49), additional lowermolecular-weight protein A-specific reactive bands were
present in the sarA mutants (Fig. 5). This is presumably due to
degradation of protein A as a result of increased proteolytic
activity in a sarA mutant (17, 49). Interestingly, protein A
showed less apparent degradation in the sarA sarT double
mutant than in the sarA mutant. However, the intensities of the
four bands seen in the sarA mutant (138, 134, 795, and 307
AIU) and the two major bands seen in the sarA sarT mutant
(1,031 and 188 AIU) added up to 1,374 and 1,219 AIU, respectively, suggesting that protein A expression was likely to be
similar in the two strains.
Gel shift and DNase I footprinting. Northern and Western
blots of sarS and spa RNA levels in various mutants led to the
hypothesis that sarT regulates sarS expression. We evaluated
the binding of the SarT protein to the region upstream of the
sarS promoter. A 264-bp region of the sarS promoter was
cloned and purified. Various concentrations of purified SarT
protein (Fig. 6A) were incubated with the 32P-end-labeled
fragment encompassing the sarS promoter region, and the
reaction mixtures were analyzed by gel shift assays (Fig. 6B).
The dose-dependent retardation in the mobility of the sarS
promoter fragment with increasing amounts of SarT (Fig. 6B)
indicated that SarT binds to the sarS promoter region. As
SarA, SarR, and possibly other SarA homologs are believed to
form dimeric structures (31), it is likely that the multiple banding pattern (Fig. 6B, third lane from the left) may result from
SarT forming dimers and tetramers on the DNA strand, since
there were only two binding sites for SarT on the sarS promoter (see below).
To confirm that binding was specific, the assay was repeated
with unlabeled sarS promoter as a competitor (Fig. 6C). The
gel shift pattern showed a dose-dependent reduction in the
intensity of the SarT-sarS promoter complex, while the intensity of the unbound sarS promoter fragment increased, indicating that the unlabeled DNA fragment containing the sarS
promoter is able to bind SarT competitively. No comparable
shift in the labeled sarS promoter region fragment was noted
when the noncompetitive sarA P3 promoter was added to the
SarT-sarS promoter DNA mix.
To verify the specificity and map the probable binding site of
SarT on the sarS promoter region, DNase I footprinting was
performed, using a 287-bp DNA fragment encompassing the
sarS promoter region (49). DNase I footprinting of the top
strand (Fig. 7A and C) showed two major protected regions,
one region corresponding to positions 147 to 167 (region I [Fig.
7C]) and one region corresponding to positions 191 to 203
(region II [Fig. 7C]) (139 to 119 bp and 95 to 83 bp upstream
of the translation start, ATG, respectively). With the bottom
strand, we found binding sites at positions 144 to 164 and 188
to 199 (Fig. 7C) (142 to 121 bp and 98 to 87 bp upstream of the
translation start, ATG, respectively) (Fig. 7B and C). The two
protected regions occur in corresponding locations on the top
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TTT, present in both the top and bottom strands of region I
and region II (Fig. 7D).
Doxycycline-dependent induction of sarT. Dose-dependent
induction of sarS and spa was used to confirm the regulatory
control of sarT on sarS. A shuttle plasmid (pALC2217) was
constructed such that sarT was placed downstream of the tetracycline-induced xyl/tetO promoter (3). sarT mutant strains of
RN6390 and SH1000 were transformed with pALC2217 or
with vector plasmid pALC2073 as a control. Tetracycline was
used in initial experiments, but the dose range required for a
suitable sarT response from the inducible promoter was too
high (data not shown). Therefore, we used doxycycline as an
alternative to induce a sarT response at a low enough dose
level to avoid an untoward response from the control strain.
Northern blots showed that sarT expression from pALC2217
occurred even in the absence of added doxycycline (Fig. 8), but
the band intensity for sarT increased with increasing amounts
of doxycycline, particularly in strain SH1000. sarS and spa
induction roughly mirrored the sarT band intensity. Collectively, these data with the tetracycline-inducible promoter system indicated that sarT induced sarS and the ensuing spa
expression.
DISCUSSION

FIG. 6. Gel shift assay of the sarS promoter. (A) Coomassie bluestained sodium dodecyl sulfate-polyacrylamide gel electrophoresis of
SarT purified from the pET14b expression vector. MW, molecular
mass standards. (B) Gel shift assay showing the effect of increasing
concentrations of SarT protein on the mobility of a 264-bp fragment
(nt 125169 to 125432) (29). The sarS promoter fragment was end
labeled with [␥-32P] ATP, and approximately 11,000 cpm was used in
each lane. Purified SarT at 0.19, 0.38, 0.56, and 0.75 g (indicated by
the thickness of the triangle over the lanes) were added to the lanes.
(C) Competition assays. Increasing amounts of unlabeled sarS fragment (specific competitor [in micrograms]) and sarA P3 promoter
fragment (nonspecific competitor [in micrograms]) (161 bp, nt 365 to
525) (4) were added to a mixture containing sarS promoter (10,000
cpm) and 0.45 g of SarT protein.

and bottom strands and are separated by approximately 23 bp
of AT-rich sequence.
A close analysis of the four protected sequences in two
regions suggested a putative conserved 12-bp SarT binding
sequence with a consensus sequence of AAATG(A/T)CAT

S. aureus exhibits complex patterns of protein expression in
response to different environmental conditions (1, 36). It is
therefore not surprising that S. aureus harbors a complex regulatory network to coordinate expression of its array of virulence proteins. The sarA/agr interface within the regulatory
system controls growth phase-mediated repression of cell wallassociated proteins and induction of late exponential to postexponential expression of a variety of extracellular toxins and
enzymes (1, 10, 14, 17, 19, 21, 23, 27, 39, 40, 46).
SarT (48) and SarS (17, 49), two recently described SarA
homologs, have been shown to be modulated by sarA and agr
in the regulatory pathway (Fig. 1). In previous studies, we have
shown that agr likely represses spa expression by down-regulating sarS (17), while the sarA locus probably activates hla
expression by down-regulating sarT (48). The above findings
are of interest because sarS and sarT, as an activator of spa and
repressor of hla, respectively, participate in divergent pathways
in regulating spa (agr2 3 sarS13 spa1) and hla (sarA2 3
sarT1 3 hla2), despite the ability of both sarA and agr to
repress sarS and sarT. In discovering that sarS expression could
be enhanced in a sarT-complemented strain (Fig. 2), we
wanted to investigate the broader relationships of sarT with
sarS within the sarA/agr regulatory network. S. aureus RN6390
was initially chosen for these studies because of its low basal
spa expression level; hence, any alteration in sarS expression
attributable to possible sarT-mediated induction can be readily
detected by examining spa expression, the target gene of sarS
(12). We found that the complemented sarT mutant of strain
RN6390 had elevated sarS expression and was able to express
spa at a high level (Fig. 2A). Parallel experiments with S.
aureus SH1000 (22) and its complemented sarT mutant also
showed expression patterns similar to those of RN6390 (Fig.
2B).
In earlier studies (17, 48), we found that sarT, sarS, and spa
expression was elevated in a sarA mutant. In this study, we
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FIG. 7. DNase I footprinting assays of the interaction of SarT with the sarS promoter. (A and B) Top-strand (A) and bottom-strand
(B) promoter fragments. Lanes: 1 to 6, labeled DNA fragments reacted with 0, 1, 2, 4, 6, and 0 g of purified SarT protein, respectively, prior to
DNase I digestion as described in the text. An A⫹G ladder was run in parallel to identify the positions of the protected regions. The positions of
protected regions I and II are marked with brackets. (C) Sequence of the promoter region upstream of sarS, showing the two protected regions
(positions 147 to 167 and positions 191 to 203 [shown in bold type]) and showing the SarT binding sites (white letters on a black background) as
deduced from the footprinting analysis. (D) Putative 12-bp sarT binding sequence deduced from the protected regions on the top and bottom
strands. Identical nucleotides are indicated by white lettering on a black background.
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FIG. 8. Doxycycline induction of sarT. Northern blots of RNA extracted from S. aureus sarT mutants of strain RN6390 (A) or SH1000
(B) harboring either pALC2073 (control; tet-inducible promoter) or
pALC2217 (tet-inducible promoter driving sarT) and grown in the
presence of 0, 35, or 50 ng of doxycycline per ml. Doxycycline was
added to late-exponential-phase cells (OD650 of 1.1), and cells were
harvested for RNA 1 and 2 h after induction. Strains harboring the
control plasmid were harvested only 2 h after the addition of doxycycline. Results are representative of multiple experiments.

found that sarS and spa expression was elevated in the sarA
sarT double mutant (Fig. 4A), suggesting that SarA may repress sarS rather than spa. However, in previous studies, spa
was found to be repressed in a sarS mutant, relative to the sarS
sarA double mutant, indicating that SarA repression of spa is
likely independent of sarS (17, 49). Taken together, these results indicate that sarA repression of spa is independent of sarT
and sarS.
We have previously shown that agr RNAIII likely regulates
spa by repressing sarS, an activator of spa expression (17).
However, the positive modulation of sarS by SarT (Fig. 2) leads
to the question whether RNAIII represses sarS transcription
directly or indirectly by suppressing sarT. A comparison of the
agr and sarT mutants (Fig. 4B) revealed that sarS and spa
expression was induced in an agr mutant strain but was almost
totally repressed in the sarT mutant and sarT agr double mutant. Further, when sarT was returned in trans to the agr sarT
mutant via a plasmid harboring the sarT gene, sarS and spa
expression returned to levels seen in the agr mutant strain,
suggesting that sarT induction of sarS may be important for spa
expression in the agr mutant strain.
To further confirm the activation of sarS by sarT, we took
advantage of an inducible promoter system that can be activated by low doses of doxycycline to express sarT in a dosedependent manner. This plasmid, upon introduction into sarT
mutants of S. aureus RN6390 and SH1000, expressed sarT, in
proportion (approximately) to the doxycycline dose, in particular during the 2-h time points (Fig. 8). At the 1-h time point,
the basal level of sarT expression (i.e., no doxycycline) remained quite high, especially in RN6390, so the induction
phenomenon was less apparent under this condition. Nevertheless, the data on the induction time point at 2 h for both
RN6390 and SH1000 indicated that SigB does not play a significant role in this sarT-sarS induction process.
Gel shift (Fig. 6) and footprinting assays (Fig. 7) confirmed
that SarT binds specifically to the sarS promoter, presumably
leading to sarS activation. The presence of multiple bands in
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gel shift assays indicated that multiple SarT dimers likely bind
to the sarS promoter. Interestingly, SarT binds to two regions
on the sarS promoter, separated by an extremely AT-rich 23-bp
region (20 of 23 bp or 87% AT). Within the AT-rich region is
a short stretch of five adenines on the top strand and four
adenines on the bottom strand which potentially may play a
role in DNA bending (2, 44), a process that has been recognized to play a role in growth phase-mediated transcriptional
regulation (51). Additionally, the binding sites covered in both
the plus and minus strands divulged a 12-bp sequence in region
I that was repeated in region II (Fig. 7C). We speculate that
this 12-bp sequence may represent a conserved binding site for
SarT. Nevertheless, additional verification with other SarT target genes should be made to confirm this hypothesis.
In sarA or agr mutant strains where repression of sarT is
relieved, sarT expression occurs during exponential growth but
is highest during the post-exponential phase (48). The repression of sarT by sarA or agr, as demonstrated by the extremely
low sarT transcriptional levels in S. aureus RN6390 (48), suggests that sarT induction may require specific environmental
activators that in vitro growth conditions replicate poorly or
that it is transitory and therefore less likely to be readily detected.
In a transcription profiling study, Dunman et al. (21) have
pointed out that the pathogenic process is a complex progression of bacterial and host interactions in a dynamically shifting
environment. We have characterized in sarT what may be a
regulatory subroutine that is activated under a specific environmental stimulus. Further studies are required to discover
the specific environmental conditions that induce expression of
sarT and subsequently sarS.
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